Drugs that contain Desirudin Recombinant
1. Iprivask patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5733874 | CANYON | Stable dry powders |
Mar, 2015
(9 years ago) | |
Market Authorisation Date: 04 April, 2003
Treatment: NA
Dosage: INJECTABLE;SUBCUTANEOUS
More Information on Dosage
IPRIVASK family patents
